Confluent Taps Industry Veteran Tom Testa as COO to Steer Aggressive Growth

SCOTTSDALE, Ariz. – May 01, 2026 – Confluent Medical Technologies, a key contract manufacturer for the global medical device industry, has appointed seasoned executive Tom Testa as its new Chief Operating Officer. The move, effective April 29th, signals a strategic reinforcement of its leadership team as the company navigates a period of unprecedented growth and market expansion.

As COO, Testa will take the helm of Confluent’s global operations, supply chain, worldwide product development, and environmental health and safety initiatives. The appointment comes as Confluent solidifies its position as a critical partner for MedTech innovators, specializing in high-demand materials like Nitinol and advanced polymers.

"We are thrilled to welcome Tom to Confluent," said Dean Schauer, the company’s President, CEO, and Chairman, in a statement. "Tom has exceptional experience in all aspects of Executive Leadership in the Medical Device Manufacturing and Development space... As Confluent continues its significant growth, the addition of Tom to our company will further enhance the strength of our industry-leading team."

Scaling Operations for a High-Growth Trajectory

Testa’s arrival is timed to manage and accelerate Confluent’s formidable expansion. The company, which applies materials science to develop and manufacture interventional devices and implants, has been on a steep growth curve. In 2025, Confluent reported annual revenue of $1.167 billion, a more than 21% increase over the previous year, continuing a multi-year trend of robust double-digit growth.

This financial success is mirrored by aggressive operational expansion. The company recently scaled up its Costa Rica operations with a new 67,000-square-foot facility to meet soaring demand for Nitinol components and complex catheters. It also established a new manufacturing site in Chattanooga, Tennessee, its first in the southeastern U.S., focused on producing critical components for cardiovascular and neurovascular devices.

Furthermore, Confluent has made strategic moves to secure its supply chain and technological edge. A pivotal partnership with ATI, backed by a joint investment of over $50 million, is set to more than triple the melt capacity for medical-grade Nitinol by 2027. This addresses a critical bottleneck in the industry, where demand for the shape-memory alloy is growing at an estimated 18% annually, driven by innovations in structural heart, neurovascular, and electrophysiology devices. This growth is further supported by a majority investment from TPG in 2022, which has provided the capital to fuel Confluent's global expansion and technological advancements.

A Proven Leader for a Pivotal Role

Tom Testa brings a wealth of experience perfectly suited to Confluent's current needs. His career is marked by leadership roles where he successfully scaled complex MedTech operations and navigated the financial intricacies of both private equity-backed and public companies.

Before joining Confluent, Testa served as CEO of Corza Medical, a global manufacturer of surgical technologies. He was previously the company’s CFO, playing an instrumental role in its formation through the complex acquisition and integration of Surgical Specialties Corporation and the TachoSil business from Takeda Pharmaceutical. His tenure at Corza was focused on enhancing customer experience and building a robust global infrastructure.

His resume also includes serving as Vice President & General Manager of the standalone Nordson Medical business, a major integrated solutions provider for the medical device sector. He transitioned into this role after Nordson acquired the Vention Medical Advanced Technologies business, where Testa was President. His deep experience with M&A integrations and managing large, multi-facility global operations will be invaluable as Confluent continues to expand its footprint, which already includes sites across the United States, Costa Rica, and India.

Navigating a Demanding and Competitive Market

The appointment comes at a crucial time in the broader medical device contract manufacturing (MDCM) market. Valued at over $79 billion in 2024, the sector is projected to surge to nearly $190 billion by 2032. This growth is fueled by medical device OEMs increasingly outsourcing manufacturing to cut costs, access specialized expertise, and focus on their core competencies of research and marketing.

However, the market is not without its challenges. Contract manufacturers face intense pressure to manage volatile global supply chains, adhere to stringent and evolving regulatory standards, and maintain impeccable quality control. In this environment, operational excellence is not just a goal but a necessity for survival and growth. A COO with Testa's background in both finance and operations is uniquely positioned to optimize processes, mitigate supply chain risks, and ensure that rapid growth does not compromise quality or compliance.

Confluent operates in some of the most technically demanding segments of the MDCM market, competing with specialized firms in Nitinol components, polymer tubing, and interventional catheters. Its focus on materials science and vertically integrated manufacturing provides a strong competitive moat. The company’s ability to offer end-to-end services—from raw material expertise in Nitinol to the design and large-scale manufacturing of complex catheter systems—makes it a sticky partner for leading medical device companies.

In his own statement, Testa acknowledged the company's unique position. “I’m excited to join Confluent at such a pivotal moment in its growth,” he said. “The company has built a strong reputation as a trusted partner to leading medical device innovators, grounded in its differentiated materials science expertise and vertically integrated manufacturing capabilities. I look forward to working with this talented team to further strengthen operational excellence, expand our global footprint, and help drive the next phase of sustainable growth for our customers and the patients they serve.” His leadership is expected to be a key factor in ensuring Confluent not only keeps pace with market demand but continues to define the leading edge of medical device innovation.